文献速递术前评估与围术期医学

将证据转化为实践:仍有很长的路要走

Translating evidence into practice: still a way to go.
PubMed 文献 · Br J Anaesth · 2022-08-02

Chiu等回顾分析MPOG数据库2015至2019年32 250例择期腹部手术患者,发现术中晶体液15-20 ml kg-1 h-1时急性肾损伤风险最低,而血管加压药使用增加与风险升高相关,但临床实践中晶体液用量逐年下降,提示证据转化仍存挑战。

要点

  • 术中晶体液15-20 ml kg-1 h-1时急性肾损伤风险最低
  • 血管加压药用量从0增至0.04 μg kg-1 min-1去甲肾上腺素当量,急性肾损伤风险增加80%
  • 尽管证据支持限制性液体,2015至2019年晶体液用量仍逐年下降

核心结论

  • 新发现支持RELIEF试验的广泛适用性,并凸显静脉晶体液量、动脉压与急性肾损伤关系的复杂性,以及将高质量证据转化为临床实践的持续挑战。

研究设计与样本

  • 回顾性分析,基于多中心围术期结局组(MPOG)数据库,纳入2015至2019年32 250例择期腹部手术患者,描述术中液体和血管加压药给药的5年趋势并探讨其与急性肾损伤的关联。

主要发现

  • 模型预测晶体液量为15-20 ml kg-1 h-1时急性肾损伤风险最低。
  • 术中血管加压药用量从0增至0.04 μg kg-1 min-1去甲肾上腺素当量时,急性肾损伤风险增加80%。
  • 研究期间术中晶体液平均用量逐年单调下降,从2015年的6.4 ml kg-1 h-1降至2019年的5.5 ml kg-1 h-1。

临床怎么用

  • 术中晶体液管理可参考15-20 ml kg-1 h-1的范围,但需结合患者个体情况。
  • 血管加压药使用增加时需关注急性肾损伤风险,尤其是剂量较高时。
  • 应关注证据与临床实践之间的差距,促进循证实践。

局限性

  • 回顾性分析设计,可能存在残余混杂。
  • 仅纳入择期腹部手术患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chiu and colleagues report a retrospective analysis describing the 5-yr trend in both intraoperative fluid and vasopressor administration in 32 250 patients undergoing elective abdominal surgery within the Multicenter Perioperative Outcomes Group (MPOG) database from 2015 to 2019, and exploring the association between these two factors and acute kidney injury. Modelling predicted the lowest risk for acute kidney injury when the administered crystalloid volume was 15-20 ml kg-1 h-1, and an 80% increase in risk for acute kidney injury as intraoperative vasopressor use increased from 0 to 0.04 μg kg-1 min-1 of norepinephrine equivalents. Although these results are consistent with those of a large, randomised trial (REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery [RELIEF]) published in 2018, the mean intraoperative volume of crystalloid administered in the current study declined monotonically through every year included, from 6.4 ml kg-1 h-1 in 2015 to 5.5 ml kg-1 h-1 in 2019. These new findings support the broad generalisability of the RELIEF trial; highlight the complexity of the relationship between intravenous crystalloid volume infused, arterial pressure, and acute kidney injury; and demonstrate the ongoing challenge of translating high-quality evidence into clinical practice.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. McIlroy DR. Translating evidence into practice: still a way to go. Br J Anaesth. 2022. PMID: 35927095. doi:10.1016/j.bja.2022.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。